Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up
| Autor: | Ricardo F. Allegri, Gabriela Cohen, Gustavo Sevlever, Fernando Ventrice, Patricio Chrem Mendez, Silvia Vazquez, Paula Harris, Ismael Calandri, Federico Nahas, María Florencia Clarens, Carlos Romero, Horacio Martinetto, Salvador M. Guinjoan, Ignacio Demey, Fernanda Tapajoz, Maria Eugenia Martin, Jorge Campos, María Julieta Russo, Ezequiel Surace |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Argentina Severity of Illness Index lcsh:RC321-571 03 medical and health sciences 0302 clinical medicine Neuroimaging Alzheimer Disease cognitive dysfunction Internal medicine mental disorders medicine Humans Dementia Longitudinal Studies 030212 general & internal medicine Prospective cohort study lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Aged neuroimaging medicine.diagnostic_test business.industry Neuropsychology biomarkers Neuropsychological test Alzheimer's disease medicine.disease Magnetic Resonance Imaging Neurology Case-Control Studies Positron-Emission Tomography Cohort Population study Female Neurology (clinical) business 030217 neurology & neurosurgery Follow-Up Studies Alzheimer's Disease Neuroimaging Initiative |
| Zdroj: | Arquivos de Neuro-Psiquiatria v.76 n.4 2018 Arquivos de neuro-psiquiatria Academia Brasileira de Neurologia instacron:ABNEURO Arquivos de Neuro-Psiquiatria, Vol 76, Iss 4, Pp 231-240 |
| Popis: | The Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI) study is a longitudinal prospective cohort of 50 participants at a single institution in Buenos Aires, Argentina. Longitudinal assessments on a neuropsychological test battery were performed on 15 controls, 24 mild cognitive impairment (MCI) patients and 12 Alzheimer's disease (AD) dementia patients. In our study population, there was a high prevalence of positive AD biomarkers in the AD group, 92.3% (12/13); and a low prevalence in the normal controls, 20%; almost half (48%) of the patients diagnosed with MCI had positive amyloid detection. After a one year, the significant differences found at baseline on neuropsychological testing were similar at the follow-up assessment even though the AD group had significantly altered its functional performance (FAQ and CDR). The exception was semantic fluency, which showed greater impairment between the AD group and MCI and normal controls respectively. For these tests, the addition of AD biomarkers as a variable did not significantly alter the variations previously found for the established clinical group's model. Finally, the one-year conversion rate to dementia was 20% in the MCI cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|